



<b>Title</b>	<b>Rationale and design of the screening of pulmonary hypertension in systemic lupus erythematosus (SOPHIE) study</b>
<b>Author(s)</b>	<b>HUANG, D; Cheng, Y; Chan, PHM; Hai, SHJJ; Yiu, KH; Tse, HF; Wong, KL; Fan, K; Li, YW; Ng, WL; Yim, CW; Wong, CJ; Tam, LS; Wong, PCH; Wong, CY; Ho, CH; Leung, AMH; Mok, CC; Lam, H; Lau, CS; Cheung, TT; Ho, CTK; Law, WY; Chan, EW; Yin, LX; Yue, WS; Mok, TM; Evora, MA; Siu, DCW</b>
<b>Citation</b>	<b>ERJ Open Research, 2018, v. 4, p. 00135-2017</b>
<b>Issued Date</b>	<b>2018</b>
<b>URL</b>	<b><a href="http://hdl.handle.net/10722/253559">http://hdl.handle.net/10722/253559</a></b>
<b>Rights</b>	<b>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</b>



# Rationale and design of the screening of pulmonary hypertension in systemic lupus erythematosus (SOPHIE) study

Duo Huang<sup>1</sup>, Yang-Yang Cheng<sup>1</sup>, Pak-Hei Chan<sup>1</sup>, Jojo Hai<sup>1</sup>, Kai-Hang Yiu<sup>1</sup>, Hung-Fat Tse<sup>1</sup>, Ka-Lam Wong<sup>2</sup>, Katherine Fan<sup>2</sup>, Ying Wah Li <sup>3</sup>, Woon-Leung Ng<sup>4</sup>, Cheuk-Wan Yim<sup>5</sup>, Cheuk-hon John Wong<sup>6</sup>, Lai-Shan Tam<sup>7</sup>, Priscilla C.H. Wong<sup>7</sup>, Chi-Yuen Wong<sup>8</sup>, Chup-Hei Ho<sup>9</sup>, Alexander M.H. Leung<sup>9</sup>, Chi-Chiu Mok<sup>10</sup>, Ho Lam<sup>11</sup>, Chak-Sing Lau<sup>12</sup>, Tommy Cheung<sup>12</sup>, Carmen Ho<sup>12</sup>, Sharon W.Y. Law<sup>13</sup>, Esther W. Chan <sup>13</sup>, Li-Xue Yin<sup>14</sup>, Wen-Sheng Yue<sup>15</sup>, Toi Meng Mok<sup>16</sup>, Mario Alberto Evora<sup>16</sup> and Chung-Wah Siu<sup>1</sup>

**ABSTRACT** Current guideline-recommended screening for pulmonary hypertension in patients with systemic sclerosis has not been evaluated in systemic lupus erythematosus (SLE), which is disproportionately prevalent in Asians.

This multicentre, cross-sectional screening study aims to study the prevalence of pulmonary hypertension among SLE patients using these guidelines, and identify independent predictors and develop a prediction model for pulmonary hypertension in SLE patients.

SLE patients from participating centres will undergo an echocardiography- and biomarker-based pulmonary hypertension screening procedure as in the DETECT study. Standard right heart catheterisation will be provided to patients with intermediate or high echocardiographic probability of pulmonary hypertension. Those with low echocardiographic probability will rescreen within 1 year. The primary measure will be the diagnosis and types of pulmonary hypertension and prevalence of pulmonary hypertension in SLE patients. The secondary measures will be the predictors and prediction models for pulmonary hypertension in SLE patients. The estimated sample size is approximately 895 participants.

The results of the SOPHIE study will be an important contribution to the literature of SLE-related pulmonary hypertension and may be immediately translatable to real clinical practice. Ultimately, this study will provide the necessary evidence for establishing universal guidelines for screening of pulmonary hypertension in SLE patients.



@ERSpublications

**Screening pulmonary hypertension among SLE patients: SOPHIE study** <http://ow.ly/3iS930hNPw>

**Cite this article as:** Huang D, Cheng Y-Y, Chan P-H, *et al.* Rationale and design of the screening of pulmonary hypertension in systemic lupus erythematosus (SOPHIE) study. *ERJ Open Res* 2018; 4: 00135-2017 [<https://doi.org/10.1183/23120541.00135-2017>].

This article has supplementary material available from [openres.ersjournals.com](http://openres.ersjournals.com)

Received: Oct 31 2017 | Accepted after revision: Nov 21 2017

This study is registered at [ClinicalTrials.gov](http://ClinicalTrials.gov) with identifier number NCT03446339.

Support statement: This study was funded by Actelion Pharmaceuticals Singapore Pte Ltd.

Conflict of interest: None declared

Copyright ©ERS 2018. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.



**Affiliations:** <sup>1</sup>Division of Cardiology, Dept of Medicine, The University of Hong Kong, Hong Kong SAR, China. <sup>2</sup>Cardiac Medical Unit, The Grantham Hospital, Hong Kong SAR, China. <sup>3</sup>Division of Cardiology, Dept of Medicine, The United Christian Hospital, Hong Kong SAR, China. <sup>4</sup>Division of Rheumatology, Dept of Medicine, The United Christian Hospital, Hong Kong SAR, China. <sup>5</sup>Rheumatology Division, Dept of Medicine, Tseung Kwan O Hospital, Hong Kong SAR, China. <sup>6</sup>Cardiology Division, Dept of Medicine, Tseung Kwan O Hospital, Hong Kong SAR, China. <sup>7</sup>Division of Rheumatology, Dept of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. <sup>8</sup>Division of Cardiology, Dept of Medicine, Queen Elizabeth Hospital, Hong Kong SAR, China. <sup>9</sup>Division of Rheumatology, Dept of Medicine, Queen Elizabeth Hospital, Hong Kong SAR, China. <sup>10</sup>Rheumatology Division, Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, China. <sup>11</sup>Cardiology Division, Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, China. <sup>12</sup>Division of Rheumatology, Dept of Medicine, The University of Hong Kong, Hong Kong SAR, China. <sup>13</sup>Centre for Safe Medication Practice and Research, Dept of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. <sup>14</sup>Dept of Echocardiography and Non-Invasive Cardiology Laboratory, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China. <sup>15</sup>Affiliated Hospital of North Sichuan Medical College and Medical Imaging Key Laboratory, Nanchong, China. <sup>16</sup>Dept of Cardiology, Centro Hospitalar Conde de São Januário, Macau SAR, China.

**Correspondence:** Chung-Wah Siu, Cardiology Division, Dept of Medicine, The University of Hong Kong, Queen Mary Hospital, 102 Pok Fu Lam Road, Hong Kong SAR, 999077, China. E-mail: cwdsiu@hku.hk

## Introduction

Pulmonary arterial hypertension is a devastating and often life-threatening complication of connective tissue diseases. In the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL), a 55-centre longitudinal US-based registry involving 3515 patients with pulmonary arterial hypertension, connective tissue disease accounted for >50% of all patients with pulmonary arterial hypertension, in which systemic sclerosis comprised the largest connective tissue disease-related pulmonary arterial hypertension [1]. Despite advances in pharmacological therapy, the majority of patients with the condition remain asymptomatic and the diagnosis is often made late in the course of the disease when most small pulmonary arteries have been obliterated, rendering this therapy ineffective. For instance, 79% of new cases of systemic sclerosis-related pulmonary arterial hypertension in the French Pulmonary Arterial Hypertension Network between 2006 and 2009 were in New York Heart Association functional class III or IV at the time of diagnosis [2]. As such, early detection of pulmonary arterial hypertension in high-risk connective tissue disease patients is recognised as a crucial next step to further improve the outcomes of this devastating condition. In the detection of pulmonary arterial hypertension in systemic sclerosis (DETECT) study in patients with systemic sclerosis [3], an echocardiography- and biomarker-based strategy has been shown to be a sensitive and noninvasive tool to identify pulmonary arterial hypertension with minimal false negatives. To date, the European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines for the diagnosis and treatment of pulmonary hypertension recommend routine annual screening tests using resting transthoracic echocardiography, diffusion capacity of the lung for carbon monoxide and biomarkers to detect pulmonary arterial hypertension in asymptomatic systemic sclerosis patients [4].

In a stark contrast to Caucasian countries, SLE is the more common connective tissue disease than systemic sclerosis in the Asia-Pacific region, with a reported incidence ranging from 0.9 to 3.1 per 100 000 population per year and a prevalence ranging from 4.3 to 45.3 per 100 000 population, 2–3-fold more prevalent than in the Caucasian population [5]. In a recent study involving a consecutive cohort of 190 patients with connective tissue disease-related pulmonary arterial hypertension between 2006 and 2014 from China, in contrast to the US-based REVEAL registry [1], SLE instead of systemic sclerosis comprised the largest proportion of all connective tissue disease-related pulmonary arterial hypertension (58.4%), whereas systemic sclerosis accounted for only 26.3% [6]. Unlike systemic sclerosis, international guidelines [4] and expert consensus [7] do not recommend routine screening for pulmonary arterial hypertension in asymptomatic SLE patients. One of the major reasons is the wide variation of the reported prevalence of pulmonary arterial hypertension in SLE patients [8–23], ranging from 0.5% to 17.5% (table 1). This is at least partly related to the heterogeneity in study design, definition of pulmonary hypertension, and, more importantly, the infrequent use of standard right heart catheterisation to confirm and classify pulmonary hypertension as in the DETECT study for systemic sclerosis. This may adversely affect the positive and negative predictive values, and thereby the cost-effectiveness of the screening procedure [3]. Equally importantly, these studies are also limited by the small sample size, typically less than 1000 participants [24–28], hampering the prospect to identify predictors of pulmonary arterial hypertension [29] as well as to develop a prediction model for the occurrence of pulmonary arterial hypertension. Furthermore, as only a few studies originated from Asian SLE cohorts [9, 13, 18, 22], the generalisability to Asian SLE patients remains questionable.

The screening of pulmonary hypertension in SLE (SOPHIE) study is a cross-sectional screening study to apply the current ESC/ERS guideline-recommended pulmonary arterial hypertension screening algorithm

TABLE 1 Reported prevalence of pulmonary hypertension in systemic lupus erythematosus

First author [ref.]	Year	Methodology	Patients n	Prevalence %
PEREZ [15]	1981	Right heart catheterisation	43	9.3
QUISMORIO [17]	1984	Right heart catheterisation	400	0.5
SIMONSON [19]	1989	Echocardiographically derived PAP >30 mmHg	36	14.0
ASHERSON [8]	1990	Right heart catheterisation	500	5.0
WINSLOW [21]	1995	Echocardiographically derived PAP >30 mmHg	36	14.0
LI [13]	1999	Echocardiography and autopsy	419	4.0
SHEN [18]	1999	Echocardiographically derived PAP >30 mmHg	84	11.0
PAN [14]	2000	Echocardiographically derived PAP >30 mmHg	786	5.8
TANAKA [20]	2002	Echocardiographically derived PAP >40 mmHg	194	6.2
GONZALEZ-LOPEZ [23]	2004	Echocardiographically derived PAP >30 mmHg	204	16.0
JOHNSON [12]	2004	Echocardiographically derived PAP >40 mmHg	129	14.0
CHUNG [9]	2006	Echocardiographically derived PAP >45 mmHg	181	11.0
FARZANEH-FAR [10]	2006	Echocardiographically derived PAP >35 mmHg	200	17.5
PRABU [16]	2009	Echocardiographically derived PAP >30 mmHg	283	4.2
LI [22]	2014	Echocardiographically derived PAP >40 mmHg	1934	3.8
GHOFRANIHA [11]	2017	Echocardiographically derived PAP >40 mmHg	50	10.0

PAP: pulmonary arterial pressure.

for systemic sclerosis to a large cohort of unselected Chinese SLE patients in Hong Kong [4]. The study objectives include: 1) to describe the prevalence of pulmonary arterial hypertension among Chinese SLE patients using the current ESC/ERS guideline-recommended screening algorithm for pulmonary arterial hypertension in systemic sclerosis, 2) to identify independent predictors of pulmonary arterial hypertension in Chinese SLE patients and 3) to develop a prediction model for pulmonary arterial hypertension in Chinese SLE patients.

## Material and methods

### Participating centres

The study will be conducted on a multicentre basis in Asia. Participating centres must have a specialised rheumatology clinic with more than 200 SLE patients actively followed up, in which >80% patients consent to participate in the study. We expect seven to 10 centres from the Asia-Pacific region.

### Patients and patient recruitment strategy

Chinese patients fulfilling the revised American College of Rheumatology (ACR) classification criteria for SLE [30] or 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE [31] from the lupus clinics in participating hospitals are eligible for the study. In addition, patients must be aged  $\geq 18$  years at enrolment and voluntarily agree to participate by providing written informed consent. Patients with SLE followed up in the participating hospitals will be identified *via* the computerised database of the clinical management system and will be contacted by a research nurse from the participating hospitals. The design and objectives of the study will then be discussed with the research nurse. An invitation information leaflet detailing the study will be provided to the candidate patients at the same time. Patients who fail or refuse to provide written informed consent will be excluded. Table 2 summarises the five items included in the study screening procedure. According to the ESC/ERS guidelines [4], standard right heart catheterisation will be provided to patients with intermediate or high echocardiographic probability of pulmonary hypertension. For those with low echocardiographic

TABLE 2 Screening procedure for pulmonary hypertension

- 1) Demographic data, data pertinent to systemic lupus erythematosus and other cardiovascular risk factors/conditions
- 2) Standard 12-lead ECG
- 3) Nail-fold video capillaroscopy
- 4) Plasma concentration brain natriuretic peptide and other biomarkers
- 5) 6-min walk distance
- 6) Echocardiography

probability of pulmonary hypertension, the screening procedure will be repeated within 1 year to ensure the true negativity (figure 1).

### Study design

SOPHIE is a multicentre, cross-sectional screening study. The study is registered with ClinicalTrials.gov (registration number NCT03446339). The study protocol has been approved by the Institutional Review Board of The University of Hong Kong and Hong Kong West Cluster, Hospital Authority, Hong Kong. Approvals from other participating hospitals will be obtained subsequently. Written consent will be obtained from each participant, and the study will be performed in accordance with the ethical standards laid down in the Declaration of Helsinki and its later amendments.

### Demographic data collection


Demographic data and ACR SLE criteria, date of SLE diagnosis, immunological abnormalities, SLEDAI-2K (SLE disease activity index-2K) score (supplementary appendix S1) and SLICC/ACR damage index (supplementary appendix S2) will be collected. Past and present treatment modalities for SLE together with the corresponding duration will also be recorded. In addition, cardiovascular risk factors, history of other cardiovascular disease and investigation results within 3 months, including serum urea, serum creatinine, estimated glomerular filtration rate and diffusion capacity of the lung for carbon monoxide, will also be recorded. Table 3 summarises the demographic data and data pertinent to SLE and other cardiovascular risk factors and/or conditions to be collected.

### Nail-fold video capillaroscopy

Prior studies have shown that microvascular abnormalities detected by nail-fold video capillaroscopy appear to be related to the disease severity and the presence of specific autoantibodies in the serum of SLE patients [32]. However, little is known about the relationship between these abnormalities and pulmonary vasculature damage. The nail-fold of the second, third, fourth and fifth fingers of both hands in each patient will be examined using an optical probe video capillaroscope equipped with a  $\times 200$  magnification contact lens and connected to image analysis software (Videocap; DS MediGroup, Milan, Italy). Patients will be inside the examination room for a minimum of 15 min before the nail-fold examination, where the temperature is kept at 21–25°C. The pattern of microangiopathy will then be classified as “early”, “active” and “late”, as previously reported in systemic sclerosis [33].

### Echocardiographic examination

Detailed quantitative transthoracic echocardiography examination including two-dimensional, M-mode and Doppler flow studies will be performed in all patients. Standard two-dimensional and M-mode measurements will be performed according to the recommendations of the American Society of Echocardiography [34]. Valvular regurgitation will be classified as “mild”, “moderate” or “severe” using a



**FIGURE 1** Study flow. SLE: systemic lupus erythematosus; BNP: brain natriuretic peptide; V/Q: ventilation/perfusion.

TABLE 3 Demographic data and data pertinent to systemic lupus erythematosus and cardiovascular diseases

<b>Demographic</b>	Age Sex
<b>SLE</b>	Age of diagnosis and disease duration Raynaud's phenomenon Telangiectasia System involvements: pleuritis, pericarditis and interstitial lung disease Immunological abnormalities: anti-RNP antibodies, anti-SSA/Ro antibodies and anticardiolipin antibodies SLEDAI-2K (supplementary appendix S1) Nail-fold video capillaroscopy: microangiopathy ("early", "active" and "late") Present and past treatment modalities and the corresponding duration for SLE
<b>Cardiovascular data</b>	
Risk factors	Hypertension, diabetes mellitus and hyperlipidaemia
Diseases	Coronary artery disease, peripheral artery disease, stroke, myocardial infarction, heart failure, atrial fibrillation and other conduction abnormalities
<b>Renal function</b>	Serum urea, serum creatinine and estimated glomerular filtration rate
<b>Lung function test</b>	Diffusion capacity of the lung for carbon monoxide

SLE: systemic lupus erythematosus; RNP: ribonucleoprotein; SSA: Sjögren's syndrome A; SLEDAI-2K: SLE disease activity index-2K score.


semiquantitative method [35]. A standard Doppler echocardiographic method will be used to estimate cardiac output [36]. For the calculation of cardiac output, an average of five consecutive ventricular systoles during sinus rhythm or an average of 13 beats in the case of atrial fibrillation will be obtained [37]. Simultaneous blood pressure measurements will be made with a calibrated noninvasive semiautomatic device (Dinamap 1846XT; Critikon, Tampa, FL, USA) during the determination of cardiac output. Total vascular resistance (TVR) will be calculated as:

$$\text{TVR dyn}\cdot\text{s}\cdot\text{cm}^{-5} = 80 \times \frac{\text{Mean arterial blood pressure mmHg}}{\text{Cardiac output L}\cdot\text{min}^{-1}}$$

For the right heart, specific transthoracic echocardiographic measurements will be performed based on the guidelines for the echocardiographic assessment of the right heart in adults from the American Society of Echocardiography, which is endorsed by the European Association of Echocardiography [38]. Specifically, right atrial dimensions will be assessed using right atrial area (normal <18 cm<sup>2</sup>), right atrial length (normal <53 mm) and right atrial diameter (normal <44 mm). Right ventricular dimensions will be estimated at the base (normal <42 mm) and at the mid level (normal <35 mm) as well as the longitudinal dimension (normal <86 mm) at end-diastole from a right ventricular-focused apical four-chamber view with images demonstrating the maximum diameter of the right ventricle without foreshortening (figure 2a). Additional right ventricular dimensions at the right ventricular outflow tract (RVOT) will be measured: 1) proximal RVOT diameter at the left parasternal long axis view for the proximal portion of the RVOT (normal <33 mm) and 2) distal RVOT diameter at the left parasternal short axis view demonstrating RVOT at the level of the pulmonic valve (normal <27 mm). Right ventricular wall thickness will be measured at the left parasternal view in diastole (normal <5 mm). In addition, right ventricular systolic function will be assessed using tricuspid annular plane systolic excursion and right ventricular fractional area change (FAC) (figure 2b and c) [1]:

$$\text{Right ventricular FAC \%} = 100 \times \frac{\text{Right ventricular end-diastolic area} - \text{Right ventricular end-systolic area}}{\text{Right ventricular end-diastolic area}}$$

Right ventricular systolic pressure will be determined using continuous-wave Doppler echocardiography. Additional parameters for estimation of the right atrium include 1) inferior vena cava diameter and 2) Caval index, which measures the respiratory collapse of the inferior vena cava [39, 40]. Additional echocardiographic signs of pulmonary hypertension include 1) dilated right ventricle with right ventricular to left ventricular basal diameter >1.0, 2) flattening of the interventricular septum, 3) dilated pulmonary artery, 4) dilated inferior vena cava and 5) dilated right atrium. In addition, the presence and the degree of



**FIGURE 2** Echocardiography view. a) Apical four-chamber view showing right atrial and ventricular dimensions. b, c) Right ventricular fractional area change (see main text for calculation): b) right ventricular end-diastolic area (yellow) and c) right ventricular end-systolic area (red).

pericardial effusion as well as the possible aetiological causes will be recorded. The echocardiographic probability of pulmonary hypertension will be classified into “low”, “intermediate” and “high” according to the 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension (table 4) [4].

#### **Right heart catheterisation**

According to the ESC/ERS guidelines [4], standard right heart catheterisation will be provided to patients with intermediate or high echocardiographic probability of pulmonary hypertension. Pulmonary arterial hypertension is defined as mean pulmonary arterial pressure  $>25$  mmHg with a pulmonary capillary wedge pressure  $\leq 15$  mmHg and pulmonary vascular resistance  $>3$  Wood units obtained at right heart catheterisation. Pulmonary hypertension will be further classified into five groups according to haemodynamic findings obtained from the right heart catheterisation, clinical presentation and other pathological findings accordingly [4].

#### **Study measures**

The primary measure will be the diagnosis and the types of pulmonary hypertension in Chinese SLE patients. The prevalence of pulmonary arterial hypertension among Chinese SLE patients will be determined. The secondary measures will be the predictors for the occurrence of pulmonary arterial hypertension in Chinese SLE patients.

#### **Sample size calculation**

The minimal sample size for the SOPHIE study is estimated based on 1) the prevalence of pulmonary arterial hypertension in SLE patients of 5–17.5%, 2) the sensitivity and specificity of the screening

**TABLE 4** Echocardiographic probability of pulmonary hypertension according to European Society of Cardiology/European Respiratory Society guidelines [4]

Right ventricular systolic pressure mmHg	Peak tricuspid regurgitation velocity $\text{m}\cdot\text{s}^{-1}$	Other echocardiographic pulmonary hypertension signs	Echocardiographic probability of pulmonary hypertension
31	2.8 or not measurable	No	Low
31	2.8 or not measurable	Yes	Intermediate
32–46	2.9–3.4	No	Intermediate
32–46	2.9–3.4	Yes	High
>46	>3.4	Not required	High

algorithm from the DETECT study of 97% and 35%, respectively, 3) the precision of estimates of sensitivity or specificity, and 4) type I error of 0.05 [41]. A minimum of 895 SLE patients will be required for a sensitivity of 97% and a precision estimate of 0.05 for the SOPHIE study. Approximately 2000 SLE patients will be recruited so that the sample size will be adequate.

### *Statistical analysis*

Continuous variables will be expressed as mean with standard deviation. Statistical comparisons between SLE patients with and without pulmonary arterial hypertension will be performed using the t-test or Fisher's exact test, as appropriate. The hazard ratio and 95% confidence interval of each variable to predict pulmonary arterial hypertension will be determined using a multivariate Cox regression model with a p-value <0.1 for inclusion. The prognostic performance of models in predicting pulmonary arterial hypertension will be assessed using c-statistics. The c-statistic for the receiver operating characteristic curve will be calculated using Analyse-it for Excel (Analyse-it, Leeds, UK) with the Delong–Delong comparison for the c-statistic. A p-value <0.05 will be considered as significant. Calculations will be performed using SPSS version 12.0 (IBM, Armonk, NY, USA) and MedCalc version 13.1.2 (MedCalc, Ostend, Belgium).

### **Discussion**

Despite advances in therapeutic options, the prognosis of pulmonary arterial hypertension remains poor. Early diagnosis of pulmonary arterial hypertension is associated with improved long-term survival and therefore early detection of pulmonary arterial hypertension in high-risk patients has been identified as a crucial next step to further improve the outcomes of this devastating condition. It is clear from the DETECT study in patients with systemic sclerosis that a multimodal approach using echocardiography and biomarkers is a sensitive, noninvasive tool to identify pulmonary arterial hypertension with minimal false negatives [3]. The approach is recommended for screening of pulmonary arterial hypertension in patients with systemic sclerosis [4]. Uncertainties exist about the extension of this strategy to other connective tissue diseases, which has not been systemically evaluated.

In the Asia-Pacific region, SLE is known to be more prevalent and severe in non-Caucasian populations; however, the body of evidence regarding Asian SLE has largely been extrapolated from studies on Asian minorities residing in the West. Indeed, the burden of connective tissue disease-related pulmonary arterial hypertension originated from SLE instead of systemic sclerosis. In fact, SLE comprises >50% of all connective tissue disease-related pulmonary arterial hypertension (58.4%) in Asians. Experience obtained from pulmonary arterial hypertension screening strategies in systemic sclerosis may serve as a model for Asian SLE patients. Extension of the screening strategy for pulmonary arterial hypertension in systemic sclerosis with known sensitivity and specificity [3] to SLE patients can harmonise and unify early detection and diagnostic strategies across different connective tissue diseases. The SOPHIE study will explore the application of the screening strategy for pulmonary arterial hypertension currently recommended for systemic sclerosis to SLE patients. As such, the SOPHIE study aims for a large sample size of at least 2000 SLE patients to ensure adequate power to document the true prevalence of pulmonary arterial hypertension. In addition, the central requirement of >80% recruitment of SLE patients is to ensure a relatively unselective study population to avoid selection or survival bias. An additional advantage of having a large study population is to allow identification of individual predictors of pulmonary arterial hypertension that can be used to develop prediction models, which can facilitate prioritisation of SLE patients for screening procedures. One of the major challenges of the SOPHIE study is that unlike the DETECT study for patients with systemic sclerosis mandating right heart catheterisation for all screened patients, in the SOPHIE study, right heart catheterisation will be performed only for patients with intermediate or high echocardiographic probability of pulmonary hypertension according to ESC/ERS guidelines [4]. Thereby, the false-negative rate based on the low echocardiographic probability of pulmonary hypertension may potentially underestimate the “true” false negativities as documented with right heart catheterisation.

In summary, we propose a cross-sectional screening study to apply the current guideline-recommended pulmonary arterial hypertension screening algorithm for systemic sclerosis to a large cohort of unselected Chinese SLE patients. The results of the SOPHIE study will provide the prevalence of pulmonary hypertension and the types of pulmonary hypertension in Chinese SLE patients. The study will also identify individual predictors for the occurrence of pulmonary arterial hypertension in Chinese SLE patients, followed by prediction model development. The SOPHIE study will be an important contribution to the SLE pulmonary hypertension literature as one of the first systemic screening studies using the established screening protocol in systemic sclerosis patients. Ultimately, this study will provide the necessary evidence for establishing universal guidelines for the screening of pulmonary hypertension in SLE patients.



## References

- 1 McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. *Eur Respir Rev* 2012; 21: 8–18.
- 2 Launay D, Sitbon O, Hachulla E, *et al.* Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. *Ann Rheum Dis* 2013; 72: 1940–1946.
- 3 Coghlan JG, Denton CP, Grunig E, *et al.* Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. *Ann Rheum Dis* 2014; 73: 1340–1349.
- 4 Galie N, Humbert M, Vachiery JL, *et al.* 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J* 2016; 37: 67–119.
- 5 Jakes RW, Bae SC, Louthrenoo W, *et al.* Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. *Arthritis Care Res* 2012; 64: 159–168.
- 6 Zhao J, Wang Q, Liu Y, *et al.* Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: a cohort study in China. *Int J Cardiol* 2017; 236: 432–437.
- 7 Khanna D, Gladue H, Channick R, *et al.* Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. *Arthritis Rheum* 2013; 65: 3194–3201.
- 8 Asherson RA, Higenbottam TW, Dinh Xuan AT, *et al.* Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. *J Rheumatol* 1990; 17: 1292–1298.
- 9 Chung SM, Lee CK, Lee EY, *et al.* Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. *Clin Rheumatol* 2006; 25: 866–872.
- 10 Farzaneh-Far A, Roman MJ, Lockshin MD, *et al.* Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. *Arthritis Rheum* 2006; 54: 3918–3925.
- 11 Ghofraniha L, Mirfeizi Z, Khabbaz FS, *et al.* Correlation of echocardiographic findings of pulmonary hypertension with six-minute walk test and plasma pro b-type natriuretic peptide level in systemic lupus erythematosus. *Electron Physician* 2017; 9: 5122–5128.
- 12 Johnson SR, Gladman DD, Urowitz MB, *et al.* Pulmonary hypertension in systemic lupus. *Lupus* 2004; 13: 506–509.
- 13 Li EK, Tam LS. Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. *J Rheumatol* 1999; 26: 1923–1929.
- 14 Pan TL, Thumboo J, Boey ML. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. *Lupus* 2000; 9: 338–342.
- 15 Perez HD, Kramer N. Pulmonary hypertension in systemic lupus erythematosus: report of four cases and review of the literature. *Semin Arthritis Rheum* 1981; 11: 177–181.
- 16 Prabu A, Patel K, Yee CS, *et al.* Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. *Rheumatology* 2009; 48: 1506–1511.
- 17 Quismorio FP Jr, Sharma O, Koss M, *et al.* Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. *Semin Arthritis Rheum* 1984; 13: 349–359.
- 18 Shen JY, Chen SL, Wu YX, *et al.* Pulmonary hypertension in systemic lupus erythematosus. *Rheumatol Int* 1999; 18: 147–151.
- 19 Simonson JS, Schiller NB, Petri M, *et al.* Pulmonary hypertension in systemic lupus erythematosus. *J Rheumatol* 1989; 16: 918–925.
- 20 Tanaka E, Harigai M, Tanaka M, *et al.* Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. *J Rheumatol* 2002; 29: 282–287.
- 21 Winslow TM, Ossipov MA, Fazio GP, *et al.* Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. *Am Heart J* 1995; 129: 510–515.
- 22 Li M, Wang Q, Zhao J, *et al.* Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus. *Lupus* 2014; 23: 1085–1091.
- 23 Gonzalez-Lopez L, Cardona-Munoz EG, Celis A, *et al.* Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. *Lupus* 2004; 13: 105–112.
- 24 Kearley K, Selwood M, Van den Bruel A, *et al.* Triage tests for identifying atrial fibrillation in primary care: a diagnostic accuracy study comparing single-lead ECG and modified BP monitors. *BMJ Open* 2014; 4: e004565.
- 25 Wiesel J, Arbesfeld B, Schechter D. Comparison of the Microlife blood pressure monitor with the Omron blood pressure monitor for detecting atrial fibrillation. *Am J Cardiol* 2014; 114: 1046–1048.
- 26 Wiesel J, Fitzig L, Herschman Y, *et al.* Detection of atrial fibrillation using a modified Microlife blood pressure monitor. *Am J Hypertens* 2009; 22: 848–852.
- 27 Stergiou GS, Karpettas N, Protogerou A, *et al.* Diagnostic accuracy of a home blood pressure monitor to detect atrial fibrillation. *J Hum Hypertens* 2009; 23: 654–658.
- 28 Gandolfo C, Balestrino M, Bruno C, *et al.* Validation of a simple method for atrial fibrillation screening in patients with stroke. *Neurol Sci* 2015; 36: 1675–1678.
- 29 Tselios K, Gladman DD, Urowitz MB. Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies. *Open Access Rheumatol* 2017; 9: 1–9.
- 30 Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997; 40: 1725.
- 31 Petri M, Orbai AM, Alarcon GS, *et al.* Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum* 2012; 64: 2677–2686.
- 32 Moneib HA, Salem SA, Aly DG, *et al.* Assessment of serum vascular endothelial growth factor and nail fold capillaroscopy changes in systemic lupus erythematosus with and without cutaneous manifestations. *J Dermatol* 2012; 39: 52–57.
- 33 Cutolo M, Sulli A, Pizzorni C, *et al.* Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. *J Rheumatol* 2000; 27: 155–160.

- 34 Cheitlin MD, Armstrong WF, Aurigemma GP, *et al.* ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). *J Am Soc Echocardiogr* 2003; 16: 1091–1110.
- 35 Helmcke F, Nanda NC, Hsiung MC, *et al.* Color Doppler assessment of mitral regurgitation with orthogonal planes. *Circulation* 1987; 75: 175–183.
- 36 Evangelista A, Garcia-Dorado D, Garcia del Castillo H, *et al.* Cardiac index quantification by Doppler ultrasound in patients without left ventricular outflow tract abnormalities. *J Am Coll Cardiol* 1995; 25: 710–716.
- 37 Dubrey SW, Falk RH. Optimal number of beats for the Doppler measurement of cardiac output in atrial fibrillation. *J Am Soc Echocardiogr* 1997; 10: 67–71.
- 38 Rudski LG, Lai WW, Afilalo J, *et al.* Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *J Am Soc Echocardiogr* 2010; 23: 685–713.
- 39 Kircher BJ, Himelman RB, Schiller NB. Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava. *Am J Cardiol* 1990; 66: 493–496.
- 40 Siu CW, Zhang XH, Yung C, *et al.* Hemodynamic changes in hyperthyroidism-related pulmonary hypertension: a prospective echocardiographic study. *J Clin Endocrinol Metab* 2007; 92: 1736–1742.
- 41 Hajian-Tilaki K. Sample size estimation in diagnostic test studies of biomedical informatics. *J Biomed Inform* 2014; 48: 193–204.